RESEARCH APPROACHES
INVESTING IN NEW TECHNOLOGIES &
APPROACHES
Cancer treatment is evolving as researchers continue to reveal the intricacies of cancer pathology and leverage this knowledge to discover novel therapeutic approaches. AbbVie is committed to leading the advancement of cancer treatment by pursuing innovative research technologies driven by our deep understanding of oncogenic pathways and biomarkers.
Core Areas of Biology
Therapeutic Modalities
Chimeric antigen receptor-T (CAR-T) cell therapy is a personalized immunotherapy that uses T cells from a patient’s own blood (autologous) or T cells from a donor (allogeneic) to fight cancer.1 A patient’s T cells are genetically engineered in a lab with a CAR designed to recognize antigens on cancer cells and then returned to the patient via intravenous (IV) infusion. MORE >
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
- Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012;23(suppl8):viii6-viii9.
- Aponte PM, Caicedo A. Stemness in cancer: stem cells, cancer stem cells, and their microenvironment. Stem Cell International. 2017.
- Fan G, Wang Z, Hao M, Li J. Bispecific antibodies and their applications. J Hematol Oncol. 2015;8:130. Doi:10.1186/s13045-015-0227-0.
- Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35(4):e00225.
- Diamantis N, Banerji U. Antibody-drug conjugates—an emerging class of cancer treatment. Br J Cancer. 2016;114(4):362-367.
- Hoelder S, et al. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol. 2012;6(2):155-76.